脑转移瘤放射治疗的系统综述
SRS联合WBRT对比单用SRS或单用WBRT在总生存上无统计学显著差异,术后放疗对比单纯手术亦未改善总生存;生活质量、功能状态与认知影响的数据不足。
要点
- SRS联合WBRT对比单用SRS或单用WBRT,总生存无统计学显著差异(HR 1.09;95%CI 0.69%-1.73%;4项RCT)。
- 术后放疗对比单纯手术未改善总生存(HR 0.98;95%CI 0.76%-1.26%;5项RCT)。
- WBRT联合系统治疗对比单用WBRT与呕吐风险增加相关(RR 1.44;95%CI 1.03%-2.00%;14项研究)。
核心结论
- 尽管放射治疗研究文献数量庞大,比较效果信息仍有限,需要更多关于生活质量、功能状态和认知影响等患者相关结局的数据。
研究设计与样本
- 证据报告综合2020年7月检索的PubMed、EMBASE、Web of Science、Scopus、CINAHL、clinicaltrials.gov及已发表指南等文献,纳入随机对照试验(RCT)和大型观察性研究(用于安全性评估)。
- 纳入研究评估WBRT和SRS单用或联合、作为初始或术后治疗、联合或不联合系统治疗,对象为肺癌、乳腺癌或黑色素瘤所致脑转移成人患者。
主要发现
- SRS联合WBRT对比单用SRS或单用WBRT,总生存无统计学显著差异(HR 1.09;95%CI 0.69%-1.73%;4项RCT),死于脑转移亦无显著差异(RR 0.93;95%CI 0.48%-1.81%;3项RCT)。
- 术后放疗对比单纯手术未改善总生存(HR 0.98;95%CI 0.76%-1.26%;5项RCT)。
- 生活质量、功能状态和认知影响的数据不足,无法确定WBRT、SRS或术后干预的影响。
- 未发现各干预在严重不良事件、不良事件数量、放射性坏死、疲乏或癫痫方面存在系统性差异。
关键数值与推荐
- SRS联合WBRT对比单用SRS或单用WBRT的总生存HR 1.09(95%CI 0.69%-1.73%;4项RCT)。
- 死于脑转移的RR 0.93(95%CI 0.48%-1.81%;3项RCT)。
- 术后放疗对比单纯手术的总生存HR 0.98(95%CI 0.76%-1.26%;5项RCT)。
- WBRT联合系统治疗对比单用WBRT的呕吐风险RR 1.44(95%CI 1.03%-2.00%;14项研究)。
临床怎么用
- 对于肺癌、乳腺癌或黑色素瘤脑转移成人患者,SRS联合WBRT对比单用SRS或单用WBRT未显示总生存获益,决策需结合其他结局。
- 术后放疗对比单纯手术未显示总生存改善,术后放疗选择应综合评估。
- WBRT联合系统治疗时需关注呕吐风险增加。
局限性
- 因干预与对照组合不同及结局数据报告不足,可分析数量受限。
- 偏倚风险不一,25项试验提前终止,主要因入组不佳。
- 生活质量、功能状态和认知影响数据不足,无法确定相关干预效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This evidence report synthesizes the available evidence on radiation therapy for brain metastases. METHODS AND MATERIALS: The literature search included PubMed, EMBASE, Web of Science, Scopus, CINAHL, clinicaltrials.gov, and published guidelines in July 2020; independently submitted data, expert consultation, and contacting authors. Included studies were randomized controlled trials (RCTs) and large observational studies (for safety assessments), evaluating whole brain radiation therapy (WBRT) and stereotactic radiosurgery (SRS) alone or in combination, as initial or postoperative treatment, with or without systemic therapy for adults with brain metastases due to lung cancer, breast cancer, or melanoma. RESULTS: Ninety-seven studies reported in 189 publications were identified, but the number of analyses was limited owing to different intervention and comparator combinations as well as insufficient reporting of outcome data. Risk of bias varied, and 25 trials were terminated early, predominantly owing to poor accrual. The combination of SRS plus WBRT compared with SRS alone or WBRT alone showed no statistically significant difference in overall survival (hazard ratio [HR], 1.09; 95% confidence interval [CI], 0.69%-1.73%; 4 RCTs) or death owing to brain metastases (relative risk [RR], 0.93; 95% CI, 0.48%-1.81%; 3 RCTs). Radiation therapy after surgery did not improve overall survival compared with surgery alone (HR, 0.98; 95% CI, 0.76%-1.26%; 5 RCTs). Data for quality of life, functional status, and cognitive effects were insufficient to determine effects of WBRT, SRS, or postsurgery interventions. We did not find systematic differences across interventions in serious adverse events, number of adverse events, radiation necrosis, fatigue, or seizures. WBRT plus systemic therapy (RR 1.44; 95% CI, 1.03%-2.00%; 14 studies) was associated with increased risks for vomiting compared with WBRT alone. CONCLUSIONS: Despite the substantial research literature on radiation therapy, comparative effectiveness information is limited. There is a need for more data on patient-relevant outcomes such as quality of life, functional status, and cognitive effects.
引用
- Garsa A, Jang JK, Baxi S, et al. Radiation Therapy for Brain Metastases: A Systematic Review. Pract Radiat Oncol. 2021. PMID: 34119447. doi:10.1016/j.prro.2021.04.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。